Nintedanib Demo (Nintedanib Esylate)

Nintedanib, the active ingredient in Nintedanib Demo, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Demo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nintedanib is indicated for fibrotic lung diseases and as part of combination therapy for certain lung cancers.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in forced vital capacity. Systemic sclerosis‑associated interstitial lung disease: helps preserve lung function and delays worsening of respiratory symptoms. Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with approved chemotherapeutic agents.

Nintedanib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Diarrhea: frequent watery stools that may lead to dehydration. - Nausea: feeling of sickness often accompanied by loss of appetite. - Vomiting: expulsion of stomach contents, sometimes intermittent. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates potential hepatic injury requiring monitoring. - Bleeding events: includes gastrointestinal hemorrhage or nosebleeds, especially with anticoagulants. - Cardiovascular complications: such as hypertension, arterial thromboembolism, or heart failure.

Before initiating Nintedanib, clinicians should evaluate several safety considerations to minimize risk.

- Monitor liver function: obtain baseline transaminases and repeat periodically during therapy. - Assess bleeding risk: review use of anticoagulants, antiplatelet agents, and history of ulcers. - Evaluate cardiovascular status: watch for hypertension or signs of arterial thromboembolism. - Avoid in severe hepatic impairment: contraindicated in patients with Child‑Pugh C liver disease. - Pregnancy and lactation: safety unknown; use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nintedanib interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure and toxicity. - Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin): heighten risk of serious bleeding. - P‑glycoprotein inhibitors (e.g., itraconazole): can raise plasma concentrations leading to adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels. - Other anti‑angiogenic or VEGF‑targeted therapies: additive risk of hypertension and vascular events.